GlassScriptPhysician profile
Tarvinder Gilotra
NPI 1902288103
$1,084.73
in general payments reported to CMS, 2019-2025
7 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $223 · 2023: $382 · 2024: $155 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.28 |
| Education | $104.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $300.86 | 2022-2024 | Nuzyra |
| Ferring Pharmaceuticals INC. | $275.96 | 2022-2025 | Rebyota |
| Astellas Pharma US INC | $153.48 | 2021-2022 | |
| Kerecis Limited | $149.11 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Insmed, INC. | $81.20 | 2022-2024 | Arikayce |
| Melinta Therapeutics, LLC | $74.50 | 2021-2023 | Vabomere, Orbactiv, Kimyrsa |
| Viiv Healthcare Company | $49.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarvinder Gilotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.